Acute heart failure

Abstract

Acute heart failure (AHF) is a syndrome defined as the new onset (de novo heart failure (HF)) or worsening (acutely decompensated heart failure (ADHF)) of symptoms and signs of HF, mostly related to systemic congestion. In the presence of an underlying structural or functional cardiac dysfunction (whether chronic in ADHF or undiagnosed in de novo HF), one or more precipitating factors can induce AHF, although sometimes de novo HF can result directly from the onset of a new cardiac dysfunction, most frequently an acute coronary syndrome. Despite leading to similar clinical presentations, the underlying cardiac disease and precipitating factors may vary greatly and, therefore, the pathophysiology of AHF is highly heterogeneous. Left ventricular diastolic or systolic dysfunction results in increased preload and afterload, which in turn lead to pulmonary congestion. Fluid retention and redistribution result in systemic congestion, eventually causing organ dysfunction due to hypoperfusion. Current treatment of AHF is mostly symptomatic, centred on decongestive drugs, at best tailored according to the initial haemodynamic status with little regard to the underlying pathophysiological particularities. As a consequence, AHF is still associated with high mortality and hospital readmission rates. There is an unmet need for increased individualization of in-hospital management, including treatments targeting the causative factors, and continuation of treatment after hospital discharge to improve long-term outcomes.

Conflict of interest statement

Competing interests

All authors declare no competing interests.

Figures

Fig. 1 |. Schematic representation of possible pathophysiological mechanisms in AHF.

Acute heart failure (HF) results from the combination of an underlying but newly diagnosed cardiac dysfunction and precipitating factors or the onset of a new cardiac dysfunction (de novo HF) or the combination of an underlying chronic cardiac dysfunction and one or more precipitating factors (acutely decompensated HF (ADHF), that is, decompensation of chronic HF). Precipitating factors may directly affect left ventricular (LV) or right ventricular (RV) function (for example, myocardial ischaemia and arrhythmias) or may contribute to the development of congestion (for example, infection, hypertension and non-compliance with treatment recommendations). LV dysfunction (diastolic dysfunction in HF with preserved ejection fraction (HFpEF) or diastolic and systolic dysfunction in HF with reduced ejection fraction (HFrEF)) leads to pulmonary congestion, which in turn contributes to RV dysfunction and systemic congestion. Systemic congestion, neurohumoral activation and inflammation negatively affect ventricular function and further contribute to self-perpetuating congestion.

Fig. 2 |. Proposed management algorithm for patients with AHF.

Congestion is assessed on the basis of the presence of compatible clinical signs (for example, pulmonary rales, distended Jugular veins and peripheral oedema), evidence of organ congestion on chest X-ray radiography or lung ultrasonography and elevated filling pressures on invasive monitoring. Abnormal peripheral perfusion is assessed on the basis of the presence of compatible clinical signs (for example, cold and clammy skin, oliguria and altered mental status) and other evidence of altered oxygen transport (for example, increased blood lactate and low central venous or mixed venous oxygen saturation). The response to fluid challenge (that is, change in cardiac output after administration of 250–500 ml of fluids), positive inotropic agents (that is, intravenous drugs that increase cardiac contractility) and vasopressors (that is, intravenous drugs that increase arterial blood pressure by causing peripheral vasoconstriction) should be closely assessed by measuring changes in stroke volume, either by echocardiography or by other invasive monitoring systems. HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MCS, mechanical circulatory support; SBP, systolic blood pressure.

Fig. 3 |. Quality of life in patients with AHF.

Physical and psychological symptoms that contribute to impaired quality of life in patients with acute heart failure (AHF).